FDA Drafts Guides to Speed Up Generic Drug Testing Processes
Published Date: 11/21/2025
Notice
Summary
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by January 20, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Draft Guidance Aims to Speed Generics
The FDA released draft product-specific guidances that give recommendations on designing bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). The notice says these updates aim to speed up drug approvals and could potentially save time and money for companies and patients alike; comments on the drafts are due January 20, 2026.
New Draft Guidances Posted for Many Drugs
FDA posted new draft product-specific guidances for ANDAs for listed active ingredients, including Aprocitentan, Berdazimer sodium, Budesonide, Carbidopa/Levodopa (multiple reference listed drugs), Tirzepatide, Travoprost, and others. Stakeholders may review these product-specific BE recommendations and submit comments by January 20, 2026.
Revised Draft Guidances Also Available
FDA posted revised draft product-specific guidances for ANDAs for listed active ingredients such as Aclidinium bromide, Amphetamine, Buprenorphine hydrochloride, Diazepam, Metronidazole, Valbenazine tosylate, and others. Interested parties may submit comments (including on costs or cost savings) and should do so by January 20, 2026.
Guidances Are FDA's Non-Binding Views
The draft guidances, when finalized, will represent FDA's current thinking on product-specific BE study design but do not establish any rights and are not binding. The notice explicitly says you may use an alternative approach if it satisfies applicable statutes and regulations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-20547, Union Pacific Railroad Co.-Abandonment Exemption-in Jefferson County, Wis.
Union Pacific Railroad wants to stop using a short 0.88-mile rail line in Jefferson County, Wisconsin, and sell it to Aztalan Bio, the only company using it. Aztalan plans to change the track near its facility but will still get rail service from Union Pacific. The final decision comes by January 12, 2026, and others have a chance to step in with financial offers within 120 days.
Next: 2025-20553, Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Special Census Program
The Census Bureau is asking for approval to keep running its Special Census Program, which helps local governments get updated population counts between the big 10-year censuses. This program affects cities, counties, and other local areas that need fresh data due to growth or changes, and it costs them to request it. The government is inviting comments for 30 more days before finalizing, so communities can plan ahead and budget for this important count.